ZFPL1 Inhibitors
Chemical inhibitors of ZFPL1 can modulate the activity of this protein by targeting various signaling pathways that contribute to its functional state. LY294002 and Wortmannin are two such inhibitors that act on the PI3K/AKT pathway. By obstructing PI3K, these chemicals can reduce the phosphorylation of AKT, which in turn can lead to the functional inhibition of ZFPL1 due to the reliance of this protein on PI3K/AKT signaling for regulatory control. Similarly, Triciribine targets the AKT kinase directly, which can interrupt the downstream signaling and thus inhibit the functional activity of ZFPL1. Rapamycin, by inhibiting the mTOR pathway, can disrupt cellular growth and proliferation signals that ZFPL1 may depend upon, effectively reducing its activity.
In addition to these, U0126 and PD98059 are selective inhibitors of MEK1/2 within the MAPK/ERK pathway. By preventing the phosphorylation of ERK, these inhibitors can affect the regulatory processes that involve ZFPL1. SB203580 and SP600125, targeting p38 MAP kinase and JNK respectively, can also suppress ZFPL1 function by interfering with the stress response and apoptosis pathways that ZFPL1 might influence. Y-27632 can inhibit ROCK, which is important for cytoskeletal organization, potentially altering the cellular framework that ZFPL1 requires for its activity. The broad-spectrum tyrosine kinase inhibitor Dasatinib can block various kinases within the Src family, leading to a broad inhibition of signaling pathways that ZFPL1 uses for activation. Lastly, GW5074 and PD168393, by inhibiting Raf and EGFR tyrosine kinases respectively, can prevent the activation of downstream components of the MAPK/ERK pathway, thereby inhibiting the functional aspects of ZFPL1 tied to these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is a kinase involved in multiple signaling pathways, including those regulating transcription factors. Inhibition of PI3K can lead to a decrease in the activity of proteins regulated by these pathways, thus functionally inhibiting ZFPL1 by reducing its regulatory capabilities. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can prevent the phosphorylation and activation of ERK, potentially leading to the functional inhibition of downstream proteins such as ZFPL1 that may rely on this signaling for activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can disrupt the signaling cascade that influences the function of various proteins, including ZFPL1, leading to its functional inhibition by preventing its participation in stress response pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mTOR pathway, which is crucial for cell growth and proliferation. Inhibiting mTOR can disrupt processes that may be vital for the function of proteins such as ZFPL1, leading to its functional inhibition through the suppression of growth signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family. Inhibiting JNK can impair the signaling required for the activation of proteins associated with cell stress responses, thereby functionally inhibiting proteins like ZFPL1 that may rely on JNK signaling for their activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, affecting cytoskeletal organization and cell motility. By inhibiting ROCK, Y-27632 can disrupt cellular structures and processes that could be essential for the function of proteins such as ZFPL1, leading to its inhibition by altering the cellular framework it may rely on. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can prevent the activation of ERK and subsequent downstream signaling, functionally inhibiting proteins like ZFPL1 that may be dependent on this pathway for activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, known to interfere with the PI3K/AKT pathway. By inhibiting PI3K, Wortmannin can decrease the phosphorylation of AKT, leading to the functional inhibition of proteins like ZFPL1 that may be regulated by this signaling cascade. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, with activity against Src family kinases. By inhibiting these kinases, Dasatinib can block the signaling pathways that are crucial for the activity of various proteins, functionally inhibiting proteins such as ZFPL1 that may be activated by these pathways. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a Raf kinase inhibitor, which impacts the MAPK/ERK pathway. By inhibiting Raf, GW5074 can prevent the downstream activation of MEK and ERK, resulting in the functional inhibition of proteins like ZFPL1 that are regulated by this signaling pathway. | ||||||